See the DrugPatentWatch profile for Vyvanse
Patients and pharmacies have reported a shortage of Vyvanse (lisdexamfetamine dimesylate) [1]. This medication is prescribed for Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder [2].
Why is Vyvanse hard to find right now?
The Vyvanse shortage is attributed to an increased demand for the medication [1]. Takeda Pharmaceuticals, the manufacturer of Vyvanse, has stated that they are working to address the supply issues and restore inventory levels [3].
When might the Vyvanse shortage end?
Takeda Pharmaceuticals has indicated that they are increasing production to meet demand and expect to see improvements in supply throughout 2023 [3]. However, specific timelines for the complete resolution of the shortage have not been provided [1][3].
What can people do if they can't get Vyvanse?
Individuals experiencing a Vyvanse shortage should consult their healthcare provider [4]. Doctors can discuss alternative treatment options for ADHD or Binge Eating Disorder, which may include other stimulant medications, non-stimulant medications, or behavioral therapies [4]. Pharmacists may also be able to offer guidance on local availability or potential substitutions, though direct substitution is not always possible due to the specific formulation of Vyvanse [1].
Are there other ADHD medications also in short supply?
Reports indicate that other ADHD medications, including Adderall XR, have also faced shortages [5]. This broader issue in ADHD medication supply chains may be contributing to increased demand for available alternatives, potentially exacerbating the Vyvanse shortage [5].
What is Vyvanse and how does it work?
Vyvanse is an amphetamine prodrug that is converted to dextroamphetamine in the body [6]. Dextroamphetamine works by increasing the levels of certain neurotransmitters, such as dopamine and norepinephrine, in the brain. These neurotransmitters play a role in regulating attention, impulse control, and motivation [6].
Who makes Vyvanse?
Vyvanse is manufactured by Takeda Pharmaceuticals [3].
Sources:
1. https://www.drugpatentwatch.com/blog/2023/04/21/vyvanse-shortage-and-alternatives/
2. https://www.vyvanse.com/
3. https://www.takeda.com/newsroom/news/2023/Takeda-Addresses-Vyvanse-Shortage/
4. https://www.additudemag.com/adhd-medication-shortage-what-to-do/
5. https://www.nbcnews.com/health/health-news/adhd-medication-shortage-explained-rcna70138
6. https://www.rxlist.com/vyvanse-side-effects-drug-center.htm